Advertisement
Canada markets open in 3 hours 55 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7312
    +0.0014 (+0.20%)
     

  • CRUDE OIL

    82.82
    +0.01 (+0.01%)
     

  • Bitcoin CAD

    87,502.72
    -3,377.18 (-3.72%)
     

  • CMC Crypto 200

    1,365.20
    -17.37 (-1.26%)
     

  • GOLD FUTURES

    2,337.60
    -0.80 (-0.03%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,507.00
    -157.50 (-0.89%)
     

  • VOLATILITY

    16.19
    +0.22 (+1.38%)
     

  • FTSE

    8,085.40
    +45.02 (+0.56%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

Five Star Equities Issues New Research Reports on ANAC, EXAS, HYGS and PODD

ACCESSWIRE

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC - News) shares declined 10.45 percent to close at $17.06 a share Friday. The stock traded between $16.99 and $19.28 on volume of 722,609 shares traded. The company recently announced that the first patient was enrolled in the Phase 3 trial of AN2728 in the Phase 3 trial of AN2728 for the topical treatment of mild-to-moderate atopic dermatitis. Shares of Anacor Pharmaceuticals are up approximately 2.0 percent year-to-date.

Get more information on Anacor Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ANAC

EXACT Sciences Corporation (NASDAQ:EXAS - News) shares spiked 5.73 percent to close at $13.66 a share Friday. The stock traded between $13.10 and $14.10 on volume of 9.28 million shares traded. The company announced the pricing of a public offering of 10.0 million shares of common stock at a price of $12.75 per share. Shares of EXACT Sciences are up approximately 16.0 percent year-to-date.

ADVERTISEMENT

Get more information on EXACT Sciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/EXAS

Hydrogenics Corporation (NASDAQ:HYGS - News)(TSX:HYG.TO - News) shares dropped 10.61 percent to close at $23.75 a share Friday. The stock traded between $23.49 and $25.50 on volume 405.984 shares traded. The company expects to realize between $7.0 and $7.5 million of revenue for the quarter ended March 31, 2014. Shares of Hydrogenics are up approximately 24.0 percent year-to-date.

Get more information on Hydrogenics free access to the in-depth equity report at:
www.FiveStarEquities.com/HYGS

Insulet Corporation (NASDAQ:PODD - News) shares fell 9.70 percent to close at $44.31 a share Friday. The stock traded between $43.52 and $49.55 on volume 2.05 million shares traded. Analysts at Jefferies Group have recently raised its price target on the company to $60.00 from $55.00. Shares of Insulet have gained approximately 20.0 percent year-to-date.

Get more information on Insulet and free access to the in-depth equity report at:
www.FiveStarEquities.com/PODD

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com